Page last updated: 2024-10-31

methylphenidate and Acute Lymphoid Leukemia

methylphenidate has been researched along with Acute Lymphoid Leukemia in 8 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Research Excerpts

ExcerptRelevanceReference
"In contrast, the cancer control group only showed improvement on parent ratings of attention (Conners' Parent Rating Scale indices; P < ."2.75Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors. ( Ashford, J; Bonner, M; Brown, R; Christensen, R; Conklin, HM; Howard, SC; Khan, RB; Morris, EB; Ogg, S; Reddick, WE; Wu, S; Xiong, X, 2010)
"To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels."2.74Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. ( Conklin, HM; Howard, SC; Jasper, BW; Khan, RB; Lawford, J; Morris, EB; Ogg, SW; Wu, S; Xiong, X, 2009)
"Children surviving acute lymphoblastic leukemia (ALL) and malignant brain tumors (BTs) have a higher incidence of attention and learning problems in school than do their healthy peers."2.71Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. ( Bonner, M; Brown, R; Christensen, R; Gururangan, S; Helton, S; Kaplan, S; Khan, RB; Mulhern, RK; Reddick, WE; Wu, S; Xiong, X, 2004)
"Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck."2.50Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014)
"Childhood cancer survivors taking MPH experience significant, though modest, deceleration of BMI and weight across the first year of MPH intervention."1.35Growth effects of methylphenidate among childhood cancer survivors: a 12-month case-matched open-label study. ( Conklin, HM; Howard, SC; Jasper, BW; Khan, RB; Lawford, J; Morris, EB; Shelso, J; Wu, S; Xiong, X, 2009)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reddick, WE5
Taghipour, DJ1
Glass, JO1
Ashford, J3
Xiong, X7
Wu, S6
Bonner, M4
Khan, RB6
Conklin, HM5
Castellino, SM1
Ullrich, NJ1
Whelen, MJ1
Lange, BJ1
Jasper, BW3
Lawford, J2
Morris, EB3
Howard, SC3
Shelso, J1
Helton, S2
Mulhern, RK3
Brown, R3
Ogg, SW1
Ogg, S1
Christensen, R3
Kaplan, S1
Gururangan, S1
Thompson, SJ1
Leigh, L1
Kun, LE1
Heideman, RL1
Gajjar, A1
Merchant, T1
Pui, CH1
Hudson, MM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719]200 participants (Anticipated)Interventional2020-11-08Recruiting
Learning Impairments Among Survivors of Childhood Cancer[NCT00576472]Phase 4469 participants (Actual)Interventional2000-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Brain White Matter Volume for Patients Versus Sibling Controls

To compare the white matter volume of patients with those of sibling controls using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.

Interventionpercentage (Mean)
Patients27
Siblings30.3

Brain White Matter Volume for Patients With Acute Lymphoblastic Leukemia Versus Brain Tumors

To compare the white matter volume of Acute Lymphoblastic Leukemia (ALL) patients with those of patients with malignant brain tumors using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.

Interventionpercentage (Mean)
Patients With ALL28.4
Patients With Brain Tumors25.5

Brain White Matter Volume for Treatment Intensity Groups and Sibling Controls

To compare the white matter volume of patients by treatment intensity groups (mild, moderate, and high) and sibling controls using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.

Interventionpercentage (Mean)
Siblings30.3
Mild Treatment Intensity28.8
Moderate Treatment Intensity25.9
High Treatment Intensity25.4

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conner's Parent Rating Scale (CPRS: Cognitive Problem T Score)

The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-9.56

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Parent Rating Scale (CPRS: ADHD T Score)

The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 and 24.36 months. (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-8.74

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Teacher Rating Scale (CTRS: Cognitive Problem T Score)

The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-eight questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-3.34

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Social Skill Rating System (SSRS-P)

The Social Skills Rating System- Parent Version (SSRS-P) is a parent rating scale of social behaviors in reference to typically developing children. Thirty eight questions are rated 0 (Never) to 3 (very often). The social skills score is norm-referenced with a mean of 100±15 where a higher score is indicative of better skills. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall7.99

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Math: Composite Standard Score

The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Math Composite score assesses the child's ability to solve calculation problems (Numerical Operations) and solve applied, word problems (Math Reasoning). Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and after completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall0.22

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Reading: Composite Standard Score

The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Reading Composite consists of Basic Reading (single word reading) and Reading Comprehension. Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-0.21

Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Spelling: Standard Score

The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Spelling score assesses the child's ability to spell words to dictation. Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and after completion of home maintenance phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-2.41

Change From Methylphenidate (MPH) Home Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Teacher Rating Scale (CTRS: ADHD T Score)

The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-eight questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Methylphenidate (MPH) Home Maintenance Phase(baseline) and upon completion of the phase. Phase completion ranged between 11.44 and 24.36 months. (NCT00576472)
Timeframe: From beginning and at completion of Methylphenidate (MPH) Home Maintenance Phase, on average 16.3 months.

InterventionT-score (Mean)
Overall-7.17

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Problem Behavior.

The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated Standard Score (Mean)
Placebo97.4890
Low Dose97.0891
Moderate Dose97.5709

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Social Skill.

The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated Standard Score (Mean)
Placebo99.4412
Low Dose101.5457
Moderate Dose101.8999

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Problem Behavior.

The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated Standard Score (Mean)
Placebo100.6084
Low Dose98.6610
Moderate Dose97.3103

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Social Skill.

The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated Standard Score (Mean)
Placebo97.6171
Low Dose100.6957
Moderate Dose102.5281

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) ADHD Index.

The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated T Score (Mean)
Placebo57.5805
Low Dose54.4226
Moderate Dose53.5317

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Cognitive Problem/Inattention Scale.

The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated T Score (Mean)
Placebo57.6595
Low Dose54.6491
Moderate Dose52.9854

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Hyperactivity Scale.

The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated T Score (Mean)
Placebo54.2138
Low Dose52.2771
Moderate Dose51.5143

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) ADHD Index.

The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks

InterventionEstimated T Score (Mean)
Placebo58.7691
Low Dose54.7438
Moderate Dose54.1974

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) Cognitive Problem/Inattention Scale.

The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated T Score (Mean)
Placebo62.7053
Low Dose59.3272
Moderate Dose59.6638

Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) Hyperactivity Scale.

The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.

InterventionEstimated T Score (Mean)
Placebo55.7638
Low Dose52.1765
Moderate Dose52.6495

Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Color Naming Time.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Color Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated T Score (Mean)
MPH (Methylphenidate)40.7031
Placebo39.8889
MPH Versus Placebo0.8142

Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Ink Color Naming Time.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Ink Color Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated T Score (Mean)
MPH (Methylphenidate)45.1094
Placebo41.7937
MPH Versus Placebo3.3157

Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Interference Score.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Interference Score have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated T Score (Mean)
MPH (Methylphenidate)52.6875
Placebo50.6349
MPH Versus Placebo2.0526

Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Word Naming Time.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Word Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated T Score (Mean)
MPH (Methylphenidate)39.0156
Placebo37.8571
MPH Versus Placebo1.1585

Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Long Delay Free Recall.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Z Score for Long Delay Free Recall has a mean of 0 and a standard deviation of 1. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated Z Score (Mean)
MPH (Methylphenidate)-0.3692
Placebo-0.2090
MPH Versus Placebo-0.1603

Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Short Delay Free Recall.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Z Score for Short Delay Free Recall has a mean of 0 and a standard deviation of 1. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated Z Score (Mean)
MPH (Methylphenidate)-0.3636
Placebo-0.3358
MPH Versus Placebo-0.0278

Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) Over Five Learning Trials.

Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Trials 1-5 have a mean T Score of 50 and Standard Deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated T Score (Mean)
MPH (Methylphenidate)44.6970
Placebo45.9403
MPH Versus Placebo-1.2433

Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Beta (Risk Taking).

Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. D' and β are derived variables from signal detection theory. β is a measure of response tendency; higher scores indicate a more conservative response pattern. β was calculated using the formula = -d'*.5*(NORMSINV(hits)-NORMSINV(false alarms)). In the case where the false alarm rate = 0 or the hit rate = 1.0, we used the standard correction of 1/2N and 1- 1/2N, respectively. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated raw score (Mean)
MPH (Methylphenidate)0.2300
Placebo0.2647
MPH Versus Placebo-0.0346

Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Commission Errors.

Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Commission errors are the raw score for the numbers of nontargets presented where the subject incorrectly responded. Accordingly, the range for this variable is 0-6 with a higher score indicative of worse performance or impulsivity. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated raw score (Mean)
MPH (Methylphenidate)3.6984
Placebo3.5970
MPH Versus Placebo0.1014

Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for d' (Sensitivity).

Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. D' and β are derived variables from signal detection theory. D' is a measure of sensitivity of a person to the signal or target; a higher score is indicative of better performance or better sustained attention. D' was calculated as z(hit) - z(commission). Z-scores were calculated using the NORMSINV function in Microsoft Excel. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated raw score (Mean)
MPH (Methylphenidate)1.6809
Placebo1.7972
MPH Versus Placebo-0.1163

Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Hit Reaction Time.

Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Hit reaction time is average reaction time in milliseconds for all correct responses when targets were presented. There is no pre-defined range for reaction time; higher score is indicative of slower processing speed. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated raw score (Mean)
MPH (Methylphenidate)350.0590
Placebo354.8515
MPH Versus Placebo-4.7925

Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Omission Errors.

Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Omission errors are the raw score for the number of targets presented where the subject did not respond. Accordingly, the range for this variable is 0-54 with a higher score indicative of worse performance or problems with sustained attention. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.

InterventionEstimated raw score (Mean)
MPH (Methylphenidate)1.8889
Placebo1.6269
MPH Versus Placebo0.2620

Best Weekly Score Measured by Conners' Parent Rating Scale (CPRS: ADHD T Score) During the 3-week Home Crossover Phase.

The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were done weekly during the 3-week Home Crossover Period with the best response being used as the measurement for the test. (NCT00576472)
Timeframe: weekly during 3-week home crossover phase

,,
InterventionT score (Mean)
Oppositional T ScoreCognitive Problems/Inattention T ScoreHyperactivity T ScoreAdhd T Score
Low Dose50.8753.1451.1453.08
Moderate Dose50.4451.7250.6352.23
Placebo49.4955.6451.9655.45

Reviews

1 review available for methylphenidate and Acute Lymphoid Leukemia

ArticleYear
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Attention; Benzhydryl Compounds; Br

2014

Trials

5 trials available for methylphenidate and Acute Lymphoid Leukemia

ArticleYear
Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.
    Journal of pediatric psychology, 2010, Volume: 35, Issue:2

    Topics: Adolescent; Attention; Brain Neoplasms; Child; Cognition; Comorbidity; Cross-Over Studies; Dopamine

2010
Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial.
    Pediatrics, 2009, Volume: 124, Issue:1

    Topics: Adolescent; Brain Neoplasms; Central Nervous System Stimulants; Child; Cognition Disorders; Comorbid

2009
Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Adolescent; Analysis of Variance; Attention; Brain Neoplasms; Central Nervous System Stimulants; Chi

2010
Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-01, Volume: 22, Issue:23

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Neoplasms; Central Nervous System S

2004
Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6

    Topics: Administration, Oral; Adolescent; Attention; Brain Neoplasms; Child; Cognition Disorders; Double-Bli

2001

Other Studies

2 other studies available for methylphenidate and Acute Lymphoid Leukemia

ArticleYear
Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:6

    Topics: Age Factors; Antineoplastic Agents; Attention; Attention Deficit Disorder with Hyperactivity; Brain;

2014
Growth effects of methylphenidate among childhood cancer survivors: a 12-month case-matched open-label study.
    Pediatric blood & cancer, 2009, Volume: 52, Issue:1

    Topics: Adolescent; Body Height; Body Mass Index; Body Weight; Brain Neoplasms; Child; Female; Growth; Human

2009